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In the last four decades, tumor immunology has shed light
on identity and functions of cells and molecules involved
in tumor rejection through the involvement of the immune
system [1]. Several groups of immune cells have been
demonstrated to be able to contrast tumor occurrence and
tumor progression by killing immunogenic tumor cells, a
phenomenon recognized under the definition of “immuno-
surveillance” [2]. Unfortunately, cancer may evade immuno-
surveillance and progress through the modifications of its
own antigens, which can reduce tumor immunogenicity
and/or increase its immunosuppressive action [3]. After years
of investigations, harnessing the immune system to attack
cancer has recently led scientists to gather enough clinical
data to show what a powerful sword immunotherapy can
be [4]. Data on unexpected clinical recoveries and long
progression-free intervals are increasing regarding patients
addressed to immunotherapy treatments [5, 6]. Despite its
extraordinary success, only a portion of cancer types and
cancer patients benefit from immunotherapy treatments.
Understanding the reason why this happens is the big chal-
lenge of our time and, in order to answer this question, basic
science is crucial: to elucidate how tumor cells and immune
cells interact with each other in cancer patients and clarify the
mechanisms through which tumormutational pattern affects
the response to therapies is the way to pursue for improving
efficacy of current treatments and promoting new anticancer
strategies. This special issue was conceived with the aim of
collecting new findings in the field of cancer immunology
and describing novel biological and molecular evidence on
the relationship between cancer and immune system as well
as cancer and immunotherapy.
In response to the aim of the special issue, four original
research papers and one review article are presented below.
The study reported by B. Cerbelli et al. from Sapienza
University of Rome, Italy, showed that immunohistochemical
PD-L1 expression in ≥25% of triple negative breast cancer
(TNBC) chemo-naı¨ve cells, derived from core biopsies, is
an independent predictor for pathological complete response
(pCR) after neoadjuvant chemotherapy, thus discussing
potentials and limits of PD-L1 future applications as a
predictive biomarker for neoadjuvant treatment response in
this subset of patients affected by such a clinically aggressive
disease.
M. Moschetta et al., at Sarah Cannon Research Institute
of London, UK, presented a study assessing the impact
of “neutrophil-to-lymphocyte ratio” (NLR) in predicting
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PFS among 55 advanced patients enrolled into PD-1/PD-L1
inhibitors phase 1 clinical trials. Results showed a significant
longer PFS in patients with a reduction of NLR after two
treatment cycles compared to the median baseline NLR,
thus advancing the hypothesis that NLR may be a helpful
predicting tool in cancer patients treated with anti-PD-1/PD-
L1 agents.
An international collaboration between USA (University
of Colorado and Yale School of Medicine) and Japan (Kindai
University and Chugai Pharmaceutical), coordinated by K.
Suda et al., obtained evidence concerning molecular mech-
anism behind the low expression of PD-1/PD-L1 in NSCLC,
associated with reduced efficacy of checkpoint inhibitors
(CI) treatments. The study highlighted that EGFR-mutated
lung cancer cell lines do not show high PD-L1 expression
and, furthermore, after acquisition of resistance to EGFR-
TKIs, EGFR phosphorylation affects PD-L1 expression, thus
identifying a molecular event able to influence the expression
of biomarkers, which regulate patients’ access to CI agents.
Apart from its immunomodulatory function, F. Zheng et
al., from Huazhong University of Science and Technology,
China, identify PD-L1 molecule as a potential biomarker
of melanoma cancer stem-like cells, since blocking PD-
L1 in melanoma cell lines expressing PD-L1 and ALDH1
impaired tumorsphere formation and induced the apoptosis
of tumorsphere cells. These findings raise the need to eluci-
date the relationship between tumor response to checkpoint
inhibitors and clonal evolution of cancer stem cells in the
future.
Finally, the review paper by M. Wei et al., Southeast
University of China, discusses the role of gastric cancer
patients’ T cells immunity and disease prognosis, providing a
critical synthesis of recent evidence on this still controversial
topic.
In conclusion, we find this special issue to be a good
opportunity for improving knowledge in the field of cancer
immunobiology and immunotherapy, which is a pivotal step
to respond adequately to the questions of our time in the
battle against cancer.
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